New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
08:15 EDTQLTIQLT Inc. decided to independently develop QLT091001 after review
QLT Inc. issued a letter to its shareholders outlining the company's recent progress and its 2013 objectives. QLT said expects its recently augmented Synthetic Oral Retinoid leadership team to meet with the FDA by the end of Q1 2013 to discuss the most prudent development path to advance QLT091001. Until the aforementioned FDA meeting is concluded, QLT does not expect to provide timelines for potential pivotal trial initiation. The company added that after evaluating the strategic options available to enhance shareholder value with respect to its Synthetic Oral Retinoid program, the board has determined at this time that independently developing QLT091001 is the most value enhancing path forward for QLT shareholders. Also, QLT reiterated its commitment to return both a significant and appropriate amount of capital to shareholders in the near term. The company's board said it hopes to be able to complete all or a significant portion of its return of capital program in the first half of 2013.
News For QLTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
10:17 EDTQLTIQLT Inc. to host special shareholder meeting
Special shareholder meeting to approve a reorganization of the company's share capital, whereby the company will distribute common shares of Aralez Pharmaceuticals to QLT shareholders in a tax efficient manner, will be held on February 11 at 1pm.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use